CDC funds more than 20 AMR-focused projects!

​Dear All: 

CDC has today announced $9m in funding for more than 20 new projects focused on slowing or combating antimicrobial resistance. Part of the CDC’s Antibiotic Resistance Solutions Initiative, these projects span a broad range that includes surveillance (C. auris, antibiotic resistance in a watershed, antibiotic resistance in poultry farms), diagnostics (POC tools, what’s in hospital sewage discharge?), fellowship training in stewardship, and much, much more. The full list with some details can be be found online at the link above and I’ve produced a high-level summary just below my signature in which I broadly classify the projects for ease of review.

Combined with the 2016 investments, CDC’s AR Solutions Initiative has awarded more than $24 million to investigators through a broad agency announcement. There’s a neat online map that shows how this has been spread across the US — I show here the map with California highlighted:


​It’s great to see our US Gov’t partners so deeply and well engaged in addressing the challenge of AMR. I’m particularly impressed by the breadth of projects … from microbiome to clinical investigations, CDC has really cast a broad net. Go CDC! 

All best wishes, –jr

John H. Rex, MD | Chief Medical Officer, F2G Ltd. | Expert-in-Residence, Wellcome Trust. Follow me on Twitter: @JohnRex_NewAbx. See past newsletters and subscribe for the future:

List of projects newly funded by CDC:


  1. Baylor College of MedicineCross-validation of human fecal minibioreactor arrays and humanized microbiota mice as complementary pre-clinical models of the GI (gastrointestinal) microbiome
  2. Regents of the University of MichiganMicrobiome disruption and Enterobacteriaceae dominance as a risk factor for sepsis in intensive care patients

Diagnostics & Bioinformatics

  1. Children’s Hospital Oakland Research Institute (CHORI) at the University of California San FranciscoRapid assays to detect Neisseria gonorrhea antibiotic resistance at the point of care
  2. Emory UniversityComputational methods for culture-independent disambiguation of wgMLST types in biological samples with multiple related bacterial strains
  3. J. Craig Venter Institute (JCVI)Improved bioinformatics tools for detection and characterization of antimicrobial resistance in public health
  4. University of Mississippi Medical CenterComparison of methods for detecting recombination in bacterial whole genome sequences


  1. Rutgers, the State University of New JerseyRapid identification and analysis of transmission of the emerging pathogen Candida auris
  2. The Ohio State University: Preventing the dissemination of CRE from healthcare facilities into surface waters in the US (continuation request)
  3. The Rector and Visitors of the University of VirginiaUnderstanding the microbiologic dynamics of Carbapenemase-producing organisms in hospital wastewater premise plumbing
  4. The University of GeorgiaThe prevalence and diversity of antibiotic resistant bacteria in a mixed-use watershed
  5. University of Alabama at BirminghamSentinel surveillance for Macrolide-resistant Mycoplasma pneumoniae at select sites in the United States

Food agriculture

  1. Georgia Tech Applied Research Corporation (GTARC)Antibiotic resistance in concentrated poultry feeding operations: Impacts on environmental waters
  2. University of Georgia Research Foundation, Inc.Azole resistance in agricultural settings


  1. Infectious Diseases Society of America (IDSA)Infectious Diseases Fellowships to drive innovative education and approaches in antibiotic resistance, antibiotic stewardship and public health (AR/AS Public Health Innovation Fellowships)
  2. OpGen, Inc.Highly accessible system for infection control and antimicrobial stewardship in resource limited settings
  3. The Children’s Hospital of Philadelphia (CHOP)Perinatal antibiotics and weight gain in childhood
  4. Translational Genomics Research Institute (TGen)Considering homologous and non-homologous recombination in outbreak analysis

Clinical investigations

  1. Cleveland VA Medical Research and Education FoundationNatural history of Clostridium difficile colonization
  2. Department of Research & Evaluation, Kaiser Permanente Southern CaliforniaPrenatal antibiotic use and body weight in children
  3. Georgia Tech Applied Research Corporation (GTARC)Optimization of therapeutic strategies to manage polymicrobial CF lung infections: Clinical assessment
  4. University of Arizona: Reducing antibacterial use in patients with coccidioidomycosis
  5. University of Maryland, BaltimoreImplementation of a novel strategy to prevent Staphylococcus aureus (SA) acquisition and hence invasive SA infection in community-based nursing homes: Feasibility and pilot to guide a multicenter stepped wedge cluster trial
  6. Washington UniversityDouble blinded, randomized controlled Trial of Oral vancomycin versus placebo in hospitalized patients with diarrhea and stool toXin NEGative but nucleic acid amplification test positive for toxigenic Clostridium difficile (TOX NEG trial)

Upcoming meetings of interest to the AMR community:


ENABLE-2 funding now includes Hit Identification & Validation

Dear All, I wrote on 25 Aug 2023 about the ENABLE-2 program and its support for hit-to-lead compound development. As a reminder, that program is focused on molecules with the potential to be direct-acting therapies for one or more of the following priority pathogens: ESBL-producing/carbapenem-resistant Enterobacteriaceae (E. coli, K. pneumoniae), P. aeruginosa, A. baumannii, methicillin-resistant S. aureus, or vancomycin-resistant E. faecium. Adding to that program, there is now an ENABLE-2

NIAID/DMID thinking for FY2026: Antibacterials, Phage, and Antifungals

Dear All, NIAID’s DMID (Division of Microbiology and Infectious Diseases) recently held a council meeting during which they proposed program concepts that encompassed both antibacterial therapies (including phage) as well as antifungal therapies for funding in FY 2026 (the year that would run from 1 Oct 2025 to 30 Sep 2026). There is no guarantee that

WHO Antibacterial Pipeline Review: Update thru 31 Dec 2023

Dear All, WHO have released an update through 31 Dec 2023 of their ongoing series of antibacterial pipeline reviews! Here are the links you need: The report: 2023 Antibacterial agents in clinical and preclinical development: an overview and analysis and a press release about the report. Infographics: Key facts and recommendations from the 2023 antibacterial agents in clinical

The (confusing!) language of AMR: ChatGPT tries to help!

Dear All (Wonkish alert! Not technical but lengthy … so settle in and enjoy the ride!): Regular readers will know of my fascination with language: e.g., this 20 Feb 2020 newsletter entitled “Language Matters: CRE vs. CPE; SDD vs. I; And MDR, XDR, PDR, UDR vs. DTR.” How about that for acronymics taken to Olympian

Scroll to Top